Navigation Links
New Report Analyzes Key Controversies in Multiple Sclerosis Treatment
Date:11/14/2007

SCOTTSDALE, Ariz., Nov. 14 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for MS therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Multiple Sclerosis," physician experts discuss the key controversies emerging from ECTRIMS (European Committee for Treatment and Research in MS) 2007, including:

-- Early aggressive therapy vs. more conservative approaches.

-- The negative results from REGARD, and implications for the powering of

MS trials. The report offers predictions on results expected in the

BEYOND, PreCISe and OLYMPUS.

-- The potential for pulmonary delivery of interferon and Copaxone.

-- The numerous orally available drugs in development for MS. The report

reviews the benefits and drawbacks of fingolimod, other S1Ps,

short-acting VLA4, teriflunomide, laquinimod, fampridine, fumarates and

other oral options, and predicts where they will fall on the

safety/efficacy spectrum.

-- The status and potential of a number of vaccine approaches.

-- Intriguing neuroprotection / neuroregeneration strategies, including

LINGO, anti-myelin-associated-glycoprotein MAb and remyelination MAb.

Drugs/Mechanisms mentioned in this report include: S1P agonists (fingolimod; Novartis, S1P1; Roche/Actelion, Sphingomab; Lpath, S1P1 modulators; Epix / Amgen), inhibitors of DNA synthesis/repair (teriflunomide; Sanofi-Aventis, cladribine; Ivax/Serono), potassium channel blockers (fampridine; Acorda, BNC-245; Bionomics), interferons (Avonex; Biogen, Rebif; Ares-Serono, Betaseron; Bayer-Schering and Biferonex; Biopartners Holdings), VLA4 inhibitors (Tysabri; Biogen/Elan, firategrast; GlaxoSmithKline, CDP-323; UCB/Biogen; ATL1102 (Antisense Therapeutics), B-cell inhibitors (rituximab; Biogen/Genentech/Roche, ocrelizumab; Genentech/Roche, CamPath/alemtuzumab; Genzyme / Bayer-Schering, ofatumumab; Genmab/GSK, GA-101; Glycart / Roche), Anti-CD-25 (daclizumab; PDL/Biogen/Roche), other autoimmune suppressants (laquinimod; Teva), myelin basic proteins (Copaxone; Teva, PI-2301 (Peptimmune), MBP8298; BioMS, BHT-3009; Bayhill, Tovaxin; Opexa, NeuroVax; Orchestra, VG-1000/RTL-1000; Artielle), fumartes (BG-12; Biogen), hormonal therapy (estriol; Pipex, testosterone; UCLA), anti-myelin-associated-glycoprotein MAb (GSK), Neurodex (dextromethorphan + quinidine; Avanir), Remyelination MAb (Acorda / Mayo).

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict Market Research
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port business ... Wistar Institute, and Sanguis, launched by a trio of students from the University of ... developing a treatment for a chronic viral infection and its associated diseases, with the ...
(Date:1/20/2017)... MA (PRWEB) , ... January ... ... leader in Less Exposure Surgery (LES®) Technologies, announced today the next evolution ... PedFuse Pedicle Screw System platform). In contrast to the competition, SpineFrontier is ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
Breaking Biology Technology:
(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):